Breaking News, Collaborations & Alliances

Glycotope Spins-out Service Business to Newly Formed FyoniBio

FyoniBio, now as part of Canton Biologics Group, will continue the contract development service business.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Glycotope GmbH, a biotechnology company developing antibodies against proteins carrying tumor-specific carbohydrate structures, and CantonBio Deutschland GmbH, a subsidiary of Canton Biologics Co. Ltd., a leading Chinese CDMO, announced the successful completion of CantonBio’s acquisition of Glycotope’s service business under the newly formed FyoniBio GmbH. The spin-out completes Glycotope’s refocus solely towards drug discovery and development, utilizing its proprietary technology platform t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters